Notice of Proposed Sale · 144
ProKidney Corp.
PROKNASDAQEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- Prokidney Corp
- Issuer CIK
- 0001850270
- Phone
- 8669554394
- Person for whose account securities are to be sold
- Brian Pereira
- Relationships to issuer
- Director
- Street
- 3929 Westpoint Blvd., Suite G
- City
- Winston-Salem
- State / country code
- NC
- Postal code
- 27103
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common | 675,235 | 945,329 | 208,926,941 | 08/18/2026 | NASDAQ | Merrill Lynch Pierce Fenner and Smith |
Broker / market maker — proposed row 1, entry 1
- Name
- Merrill Lynch Pierce Fenner and Smith
- Street
- 100 Federal St
- Street (continued)
- 12th Fl
- City
- Boston
- State / country code
- MA
- Postal code
- 02110
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Common | 01/17/2022 | Purchase of Shares | ProKidney Corp | 675,235 | N | 01/17/2022 | Cash |
Sales reported in the preceding three months
| Seller | Security | Sale date | Amount sold | Gross proceeds |
|---|---|---|---|---|
| Brian Pereira | Common | 08/18/2026 | 27,826 | 38,154.23 |
Seller — prior-sale row 1, entry 1
- Name
- Brian Pereira
- Street
- C/O Prokidney Corp
- Street (continued)
- 3929 Westpoint Blvd., Suite G
- City
- Winston-Salem
- State / country code
- NC
- Postal code
- 27103
Prior-sale reporting
- Nothing to report for the preceding three months
- N
Remarks
Brian Pereira 2012 Trust
Notice signature
- Notice date
- 08/18/2026
- Signed
- Sunita Pereira, ttee Brian Pereira 2012 Irrev Trust
Company context
ProKidney, a pioneer in the treatment of CKD through innovations in cell therapy, was founded in 2015 after a decade of research. ProKidney’s lead product candidate, rilparencel (also known as REACT®), is a first-in-class, patented, proprietary autologous cell therapy with regenerative medicine advanced therapy designation that is being evaluated in the ongoing Phase 3 REGEN-006 (PROACT 1) study for its potential to preserve kidney function in patients with advanced CKD and type 2 diabetes. For more information, please visit www.prokidney.com.